Cocrystal Pharma Inc COCP 深 滬
已收盤 04-02 16:00:00 美东时间
1.51
+0.490
+48.04%
華盛通- 最 高2.0299
- 今 開1.71
- 成交量 1.37亿股
- 最 低 1.36
- 昨 收 1.02
- 總市值 2081.39万
- 52周最高 2.67
- 市盈率 靜 --
- 換手率 994.88%
- 52周最低 0.8588
- 委 比 -44.46%
- 總股本 1378.41万
- 歷史最高 66.00
- 量 比 3667.37
- 振 幅 65.68%
- 歷史最低 0.8588
- 每 手 1
- 風險率 0.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Profusa (NASDAQ:PFSA) stock rose 48.6% to $0.86 during Thursday's regu...
04-03 01:05
Cocrystal Pharma Says FDA Grants Fast Track Designation To Its Direct-Acting Protease Inhibitor, CDI-988, Oral Antiviral Candidate Being Developed For Treatment And Prophylaxis Of Norovirus Infection
FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide economic
04-02 20:04
Cocrystal Pharma Q4 EPS $(0.17) Beats $(0.21) Estimate
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 46.88 percent increase over losses of $(0.32) per share from
03-31 20:14
Cocrystal Pharma Announces First Subjects Dosed In Phase 1b Norovirus Challenge Study To Evaluate CDI-988 As Both Preventive And Treatment For Norovirus Infections
CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988No approved treatments or
03-09 20:05
Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares
Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares Phillip Frost, MD, a Director and 10% Owner, reported the acquisition of common shares of Cocrystal Pharma Inc. The full filing can be accessed through the link below. Disclaimer: This news brief was created b
02-10 05:10
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Cocrystal Pharma, Inc. has received IRB approval to initiate a Phase 1b study for CDI-988, an oral antiviral candidate targeting norovirus infections. Enrollment begins Q1 2026, with the study evaluating CDI-988 for both prevention and treatment of norovirus, currently without approved therapies or vaccines. The double-blind, placebo-controlled study at Emory University will involve 40 healthy participants, assessing symptom reduction, viral shed...
2025-12-18 13:00
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its CFO and co-CEO, James Martin, will present updates on the company and its clinical progress at NobleCon 21 on December 3, 2025, at 10:00 am Eastern Time. The event will be held at Florida Atlantic University in Boca Raton, Florida. Investors and guests can attend with a discounted rate using the code COCPNOBLECON. A video webcast of the presentation will be available the following day on th...
2025-12-01 13:00
Cocrystal Pharma Expects To Initiate CDI-988 Phase 1b Norovirus Challenge Study In Q1 2026
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026Granted NIH SBIR award to advance influenza A/B
2025-11-14 21:29
Cocrystal Pharma Q3 EPS $(0.19) Beats $(0.21) Estimate
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 61.22 percent increase over losses of $(0.49) per share from
2025-11-14 21:27
Cocrystal Pharma Awarded Roughly $500K Phase 1 Award From National Institutes of Health's National Institute of Allergy and Infectious Diseases To Support Development Of Antiviral Candidate To Treat Influenza A And B Infections
Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company") announces it has received a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) National Institute of
2025-10-27 20:04
